Taurus Agricultural Marketing Inc.
January 21, 2026
We are proud to announce that CG P2X was awarded Winner of the Agronomics Category at the Manitoba Ag Days Innovation Showcase.
CG P2X is a root-activated, high-efficiency phosphate built on proven Crystal Green technology and designed to deliver value where it matters most: in the soil, in the plant, and on the balance sheet. By remaining protected from soil fixation and becoming available only when roots demand it, CG P2X allows crops to access phosphorus more efficiently throughout the growing season.
In 2025, Taurus conducted a series of field trials comparing CG P2X to conventional phosphorus sources using an equal dollar per acre investment. The results showed that CG P2X consistently matched yield performance while being applied at lower rates. This demonstrates that phosphorus efficiency, not volume, is the key driver of performance and return on investment.
From an economic perspective, CG P2X enables growers to:
• Maintain yield at an equal input spend
• Reduce applied phosphorus rates without compromising performance
• Improve nutrient efficiency and protect fertilizer dollars
• Build more resilient fertility programs under tightening margins
This combination of agronomic reliability and economic accountability is what set CG P2X apart in the Agronomics Category. The innovation lies not only in the chemistry, but in the ability to rethink phosphorus management without increasing financial risk.
The Manitoba Ag Days Innovation Showcase recognizes advancements that move agriculture forward through practical, science-based solutions. We extend our sincere thanks to Manitoba Ag Days, the Innovation Showcase judges, and the Agronomics Category sponsor, the Manitoba Co-operator, for supporting innovation that delivers real value to Canadian growers.
Thank you as well to the growers, agronomists, and partners who participated in this year’s trial work. Their willingness to test new approaches is what continues to push fertility strategies forward.
Contact Us To learn more about CG P2X and review trial insights.
